India Prostate Cancer Market - 2025 -2033
India Prostate Cancer Treatment Market: Industry Outlook
The India Prostate Cancer Treatment market reached US$ 12,146.00 Million in 2023, with a rise of US$ 13,220.00 Million in 2024 and is expected to reach US$ 28,097.00 Million by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033 | According to DataM Intelligence.
The India prostate cancer treatment market is growing due to rising awareness, improved healthcare infrastructure, and the increasing prevalence of prostate cancer among the aging male population. Technological advancements in diagnostics, such as PSA testing and multiparametric MRI, are enabling earlier and more accurate disease identification. The market is also witnessing increased adoption of advanced therapies like minimally invasive robotic surgeries, hormone therapies, and radiation-based modalities.
However, the high cost of these treatments, limited accessibility in rural and semi-urban areas, and lack of insurance penetration and cancer-specific reimbursement support hinder widespread adoption. Government and private sector initiatives aimed at enhancing cancer care infrastructure, spreading awareness, and improving early screening are expected to support market growth. The prostate cancer treatment market holds promising potential as India's healthcare ecosystem evolves.
India Prostate Cancer Treatment Market Dynamics: Drivers & Restraints
Driver: Rise in the prevalence of prostate cancer
The rising prevalence of prostate cancer in India is driving the growth of the treatment market. As awareness of prostate health improves and access to diagnostic services expands, more men are being diagnosed, especially in urban and semi-urban areas.
For instance, Prostate cancer, accounting for 5.4% of Indian men's cancers, is increasing, with annual cases potentially doubling by 2040. Metropolitan cities report higher incidence rates, likely due to lifestyle factors and increased awareness, leading to more diagnoses.
Healthcare providers are enhancing their oncology services, while pharmaceutical and biotech companies are intensifying research to introduce personalized and less invasive treatment options. Hospitals are investing in advanced technologies for early detection and precision treatment, boosting the overall market.
The shift towards early diagnosis, driven by improved awareness campaigns and routine screening programs, is increasing the demand for therapeutic interventions. Government bodies and private stakeholders are focusing on strengthening cancer care infrastructure, training specialists, and enhancing access to medications.
Driver: Increasing awareness and early screening initiatives
The India prostate cancer treatment market is experiencing growth due to increased awareness and early screening initiatives. Historically, prostate cancer has been underdiagnosed in India due to a lack of awareness, limited access to healthcare facilities, and cultural hesitation among men. However, recent years have seen a shift towards proactive healthcare behavior among the male population, driven by government health programs, NGO-led awareness campaigns, and private sector health initiatives.
Stakeholders like the Ministry of Health, the Indian Cancer Society, and private hospitals are promoting awareness about prostate cancer symptoms, risk factors, and early detection. The introduction of affordable diagnostic tools like PSA tests has made early screening more accessible, even in semi-urban and rural regions.
This has led to an increase in early-stage diagnoses, with treatment options such as active surveillance, minimally invasive robotic surgeries, and advanced radiation therapies being highly effective. Collaborations between pharmaceutical companies and diagnostic labs are enabling bundled screening packages and mobile diagnostic units, expanding the reach of screening programs to underserved areas.
Restraint: High cost of advanced treatments and diagnostic tools
The India prostate cancer treatment market faces significant challenges due to the high cost of advanced treatments and diagnostic tools. While advanced therapies like robotic-assisted surgeries and IMRT have improved clinical outcomes, affordability remains a major concern for patients, particularly in tier-2 and tier-3 cities. These treatments are primarily available in high-end private hospitals and specialty centers, making them prohibitive for middle- and lower-income groups. Diagnostic advancements like multiparametric MRI, genomic testing, and fusion biopsy are expensive and not widely accessible in public healthcare facilities. The lack of comprehensive insurance coverage further exacerbates the issue, leading to high out-of-pocket expenses and treatment delays. This economic disparity limits early adoption and slows market expansion despite growing disease awareness. Addressing this challenge will require strategic policy interventions, public-private partnerships, and subsidies to improve affordability and ensure equitable access to advanced prostate cancer diagnostics and treatments across all socio-economic groups in India.
Opportunity: Expansion of advanced diagnostic and treatment technologies
The India Prostate Cancer Treatment Market is experiencing significant growth due to the increasing adoption of advanced diagnostic and treatment technologies. Traditional diagnostic methods like digital rectal exams and PSA testing are being replaced by more advanced techniques like MRI fusion-guided biopsies, PET scans, and genomic profiling. These tools offer better accuracy in detecting and staging the disease, enabling clinicians to tailor treatments more effectively.
Technological innovation is also reshaping the treatment landscape, with robotic-assisted surgeries, high-intensity focused ultrasound (HIFU), image-guided radiation therapy (IGRT), and advanced hormonal and immunotherapies gaining traction, especially in tier-1 and tier-2 cities.
These technologies offer improved precision, reduced recovery time, and fewer side effects, making them attractive options for healthcare providers and patients. India's growing pool of skilled oncologists, urologists, and radiologists is well-positioned to support the adoption of these innovations.
India Prostate Cancer Treatment Market Segment Analysis
The India prostate cancer treatment market is segmented based on stage, therapy type, end user, and region.
Therapy Type:
The radiation therapy segment in the prostate cancer treatment market was valued at US$ 3,478 Million in 2024 and is estimated to reach US$ 9,054 Million by 2033, growing at a CAGR of 11.2% during the forecast period from 2025-2033.
The India Prostate Cancer Treatment Market is thriving due to the growth of the radiation therapy segment, driven by technological advancements, growing awareness, and the availability of specialized oncology centers.
For instance, in October 2024, Aster DM Healthcare, India's largest integrated healthcare company, became the first facility in the country to implement Intra-Operative Electron Radiation Therapy (IOeRT), marking a significant shift in cancer treatment. The new state-of-the-art medical facility is located at the Aster International Institute of Oncology (AIIO) at Aster Whitefield Hospital, Bengaluru. AIIO, a center of excellence for comprehensive cancer care, specializes in cutting-edge treatments and robotic surgery, including the first SGRT in Karnataka.
Radiation therapy is preferred due to its non-invasive nature and ability to precisely target cancerous tissues, sparing healthy organs. Advanced radiation modalities like Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), and Stereotactic Body Radiotherapy (SBRT) have improved clinical outcomes, reduced side effects, and enhanced patient quality of life.
The growing demand for organ-preserving treatment options, particularly for the working-age population, is also driving the growth of this segment. Increased government and private sector investment in cancer care infrastructure, including new radiotherapy units, is expanding access to these treatments.
Moreover, reimbursement schemes under public health programs and insurance coverage are also encouraging the adoption of radiation-based therapies. The training and certification of radiation oncologists are improving, addressing the shortage of skilled professionals.
India Prostate Cancer Treatment Market – Major Players
The major players in the India prostate cancer treatment market include Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Hetero Healthcare, Alkem Labs, Astellas Pharma, AstraZeneca, Bayer AG, Dendreon Pharmaceuticals, Ferring B.V., and Johnson & Johnson (Janssen Pharmaceuticals), among others.
India Prostate Cancer Treatment Market – Key Developments
The India Prostate Cancer Treatment Market is predicted to experience significant growth in the coming years due to the increasing geriatric population, early diagnosis rates, and access to advanced treatment technologies. This growth will be driven by increased awareness, improved screening initiatives, and investment in oncology infrastructure. Technological advancements, particularly robotic-assisted surgeries, will gain traction in urban centers. The government's focus on non-communicable disease management will support long-term expansion.
The India prostate cancer treatment market report delivers a detailed analysis with 50 key tables, more than 61 visually impactful figures, and 205 pages of expert insights, providing a complete view of the market landscape.
The India Prostate Cancer Treatment market reached US$ 12,146.00 Million in 2023, with a rise of US$ 13,220.00 Million in 2024 and is expected to reach US$ 28,097.00 Million by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033 | According to DataM Intelligence.
The India prostate cancer treatment market is growing due to rising awareness, improved healthcare infrastructure, and the increasing prevalence of prostate cancer among the aging male population. Technological advancements in diagnostics, such as PSA testing and multiparametric MRI, are enabling earlier and more accurate disease identification. The market is also witnessing increased adoption of advanced therapies like minimally invasive robotic surgeries, hormone therapies, and radiation-based modalities.
However, the high cost of these treatments, limited accessibility in rural and semi-urban areas, and lack of insurance penetration and cancer-specific reimbursement support hinder widespread adoption. Government and private sector initiatives aimed at enhancing cancer care infrastructure, spreading awareness, and improving early screening are expected to support market growth. The prostate cancer treatment market holds promising potential as India's healthcare ecosystem evolves.
India Prostate Cancer Treatment Market Dynamics: Drivers & Restraints
Driver: Rise in the prevalence of prostate cancer
The rising prevalence of prostate cancer in India is driving the growth of the treatment market. As awareness of prostate health improves and access to diagnostic services expands, more men are being diagnosed, especially in urban and semi-urban areas.
For instance, Prostate cancer, accounting for 5.4% of Indian men's cancers, is increasing, with annual cases potentially doubling by 2040. Metropolitan cities report higher incidence rates, likely due to lifestyle factors and increased awareness, leading to more diagnoses.
Healthcare providers are enhancing their oncology services, while pharmaceutical and biotech companies are intensifying research to introduce personalized and less invasive treatment options. Hospitals are investing in advanced technologies for early detection and precision treatment, boosting the overall market.
The shift towards early diagnosis, driven by improved awareness campaigns and routine screening programs, is increasing the demand for therapeutic interventions. Government bodies and private stakeholders are focusing on strengthening cancer care infrastructure, training specialists, and enhancing access to medications.
Driver: Increasing awareness and early screening initiatives
The India prostate cancer treatment market is experiencing growth due to increased awareness and early screening initiatives. Historically, prostate cancer has been underdiagnosed in India due to a lack of awareness, limited access to healthcare facilities, and cultural hesitation among men. However, recent years have seen a shift towards proactive healthcare behavior among the male population, driven by government health programs, NGO-led awareness campaigns, and private sector health initiatives.
Stakeholders like the Ministry of Health, the Indian Cancer Society, and private hospitals are promoting awareness about prostate cancer symptoms, risk factors, and early detection. The introduction of affordable diagnostic tools like PSA tests has made early screening more accessible, even in semi-urban and rural regions.
This has led to an increase in early-stage diagnoses, with treatment options such as active surveillance, minimally invasive robotic surgeries, and advanced radiation therapies being highly effective. Collaborations between pharmaceutical companies and diagnostic labs are enabling bundled screening packages and mobile diagnostic units, expanding the reach of screening programs to underserved areas.
Restraint: High cost of advanced treatments and diagnostic tools
The India prostate cancer treatment market faces significant challenges due to the high cost of advanced treatments and diagnostic tools. While advanced therapies like robotic-assisted surgeries and IMRT have improved clinical outcomes, affordability remains a major concern for patients, particularly in tier-2 and tier-3 cities. These treatments are primarily available in high-end private hospitals and specialty centers, making them prohibitive for middle- and lower-income groups. Diagnostic advancements like multiparametric MRI, genomic testing, and fusion biopsy are expensive and not widely accessible in public healthcare facilities. The lack of comprehensive insurance coverage further exacerbates the issue, leading to high out-of-pocket expenses and treatment delays. This economic disparity limits early adoption and slows market expansion despite growing disease awareness. Addressing this challenge will require strategic policy interventions, public-private partnerships, and subsidies to improve affordability and ensure equitable access to advanced prostate cancer diagnostics and treatments across all socio-economic groups in India.
Opportunity: Expansion of advanced diagnostic and treatment technologies
The India Prostate Cancer Treatment Market is experiencing significant growth due to the increasing adoption of advanced diagnostic and treatment technologies. Traditional diagnostic methods like digital rectal exams and PSA testing are being replaced by more advanced techniques like MRI fusion-guided biopsies, PET scans, and genomic profiling. These tools offer better accuracy in detecting and staging the disease, enabling clinicians to tailor treatments more effectively.
Technological innovation is also reshaping the treatment landscape, with robotic-assisted surgeries, high-intensity focused ultrasound (HIFU), image-guided radiation therapy (IGRT), and advanced hormonal and immunotherapies gaining traction, especially in tier-1 and tier-2 cities.
These technologies offer improved precision, reduced recovery time, and fewer side effects, making them attractive options for healthcare providers and patients. India's growing pool of skilled oncologists, urologists, and radiologists is well-positioned to support the adoption of these innovations.
India Prostate Cancer Treatment Market Segment Analysis
The India prostate cancer treatment market is segmented based on stage, therapy type, end user, and region.
Therapy Type:
The radiation therapy segment in the prostate cancer treatment market was valued at US$ 3,478 Million in 2024 and is estimated to reach US$ 9,054 Million by 2033, growing at a CAGR of 11.2% during the forecast period from 2025-2033.
The India Prostate Cancer Treatment Market is thriving due to the growth of the radiation therapy segment, driven by technological advancements, growing awareness, and the availability of specialized oncology centers.
For instance, in October 2024, Aster DM Healthcare, India's largest integrated healthcare company, became the first facility in the country to implement Intra-Operative Electron Radiation Therapy (IOeRT), marking a significant shift in cancer treatment. The new state-of-the-art medical facility is located at the Aster International Institute of Oncology (AIIO) at Aster Whitefield Hospital, Bengaluru. AIIO, a center of excellence for comprehensive cancer care, specializes in cutting-edge treatments and robotic surgery, including the first SGRT in Karnataka.
Radiation therapy is preferred due to its non-invasive nature and ability to precisely target cancerous tissues, sparing healthy organs. Advanced radiation modalities like Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), and Stereotactic Body Radiotherapy (SBRT) have improved clinical outcomes, reduced side effects, and enhanced patient quality of life.
The growing demand for organ-preserving treatment options, particularly for the working-age population, is also driving the growth of this segment. Increased government and private sector investment in cancer care infrastructure, including new radiotherapy units, is expanding access to these treatments.
Moreover, reimbursement schemes under public health programs and insurance coverage are also encouraging the adoption of radiation-based therapies. The training and certification of radiation oncologists are improving, addressing the shortage of skilled professionals.
India Prostate Cancer Treatment Market – Major Players
The major players in the India prostate cancer treatment market include Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Hetero Healthcare, Alkem Labs, Astellas Pharma, AstraZeneca, Bayer AG, Dendreon Pharmaceuticals, Ferring B.V., and Johnson & Johnson (Janssen Pharmaceuticals), among others.
India Prostate Cancer Treatment Market – Key Developments
- In May 2025, Sarvodaya Hospital in Faridabad, India, became the first theranostics and nuclear medicine center in the country to offer Terbium-161 PSMA therapy for advanced prostate cancer patients, marking a significant breakthrough in the treatment of metastatic castration-resistant or hormone-refractory prostate cancer.
- In April 2025, the Tata Memorial Centre in India launched MenCan, a non-profit initiative by the Urologic Oncology Disease Management Group, to address prostate, penile, and testicular cancers, which are increasing in incidence across the country.
The India Prostate Cancer Treatment Market is predicted to experience significant growth in the coming years due to the increasing geriatric population, early diagnosis rates, and access to advanced treatment technologies. This growth will be driven by increased awareness, improved screening initiatives, and investment in oncology infrastructure. Technological advancements, particularly robotic-assisted surgeries, will gain traction in urban centers. The government's focus on non-communicable disease management will support long-term expansion.
The India prostate cancer treatment market report delivers a detailed analysis with 50 key tables, more than 61 visually impactful figures, and 205 pages of expert insights, providing a complete view of the market landscape.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Stage
2.4. Snippet by Therapy Type
2.5. Snippet by End User
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Prostate Cancer
3.1.1.2. Increasing Awareness and Early Screening Initiatives
3.1.1.3. Advancements in Treatment Modalities
3.1.2. Restraints
3.1.2.1. High Cost of Advanced Treatments and Diagnostic Tools
3.1.2.2. Limited Access to Specialized Care in Rural Areas
3.1.2.3. Low Awareness and Social Stigma in Early Stages
3.1.3. Opportunity
3.1.3.1. Expansion of Advanced Diagnostic and Treatment Technologies
3.1.3.2. Growth of Private Healthcare Infrastructure and Medical Tourism
3.1.3.3. Collaborations for Localized Manufacturing and Clinical Trials
3.1.4. Impact Analysis
4. INDIA PROSTATE CANCER TREATMENT MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established products & Services
4.2. Latest Developments and Breakthroughs
4.3. Porter’s Five Force Analysis
4.4. Supply Chain Analysis
4.5. Patent Analysis
4.6. SWOT Analysis
4.7. Unmet Needs and Gaps
4.8. Recommended Strategies for Market Entry and Expansion
4.9. Pricing Analysis and Price Dynamics
5. INDIA PROSTATE CANCER TREATMENT MARKET: BY STAGE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
5.1.2. Market Attractiveness Index, By Stage
5.2. Stage I*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Stage II
5.4. Stage III
5.5. Stage IV
6. INDIA PROSTATE CANCER TREATMENT MARKET: BY THERAPY TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
6.1.2. Market Attractiveness Index, By Therapy Type
6.2. Chemotherapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Docetaxel
6.2.4. Cabazitaxel
6.2.5. Mitoxantrone
6.2.6. Others
6.3. Hormone therapy
6.3.1. Leuprolide
6.3.2. Goserelin
6.3.3. Triptorelin
6.3.4. Degarelix
6.3.5. Relugolix
6.4. Targeted therapy
6.4.1. Rucaparib
6.4.2. Olaparib
6.4.3. Talazoparib
6.4.4. Niraparib plus abiraterone
6.5. Immunotherapy
6.5.1. Dostarlimab
6.5.2. Pembrolizumab
6.5.3. Sipuleucel-T
6.6. Surgery
6.6.1. Radical prostatectomy
6.6.2. Transurethral resection of the prostate (TURP)
6.6.3. Orchiectomy
6.7. Radioligand Therapy
7. INDIA PROSTATE CANCER TREATMENT MARKET: BY END USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
7.1.2. Market Attractiveness Index, By End User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Oncology Centers
7.4. Rehabilitation Centers
7.5. Others
8. INDIA PROSTATE CANCER TREATMENT MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Sun Pharmaceutical Industries Ltd*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. Dr. Reddy’s Laboratories
10.3. Hetero Healthcare
10.4. Alkem Labs
10.5. Astellas Pharma
10.6. AstraZeneca
10.7. Bayer AG
10.8. Dendreon Pharmaceuticals
10.9. Ferring B.V
10.10. Johnson & Johnson (Janssen Pharmaceuticals) (LIST NOT EXHAUSTIVE)
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Stage
2.4. Snippet by Therapy Type
2.5. Snippet by End User
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Prostate Cancer
3.1.1.2. Increasing Awareness and Early Screening Initiatives
3.1.1.3. Advancements in Treatment Modalities
3.1.2. Restraints
3.1.2.1. High Cost of Advanced Treatments and Diagnostic Tools
3.1.2.2. Limited Access to Specialized Care in Rural Areas
3.1.2.3. Low Awareness and Social Stigma in Early Stages
3.1.3. Opportunity
3.1.3.1. Expansion of Advanced Diagnostic and Treatment Technologies
3.1.3.2. Growth of Private Healthcare Infrastructure and Medical Tourism
3.1.3.3. Collaborations for Localized Manufacturing and Clinical Trials
3.1.4. Impact Analysis
4. INDIA PROSTATE CANCER TREATMENT MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established products & Services
4.2. Latest Developments and Breakthroughs
4.3. Porter’s Five Force Analysis
4.4. Supply Chain Analysis
4.5. Patent Analysis
4.6. SWOT Analysis
4.7. Unmet Needs and Gaps
4.8. Recommended Strategies for Market Entry and Expansion
4.9. Pricing Analysis and Price Dynamics
5. INDIA PROSTATE CANCER TREATMENT MARKET: BY STAGE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
5.1.2. Market Attractiveness Index, By Stage
5.2. Stage I*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Stage II
5.4. Stage III
5.5. Stage IV
6. INDIA PROSTATE CANCER TREATMENT MARKET: BY THERAPY TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
6.1.2. Market Attractiveness Index, By Therapy Type
6.2. Chemotherapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Docetaxel
6.2.4. Cabazitaxel
6.2.5. Mitoxantrone
6.2.6. Others
6.3. Hormone therapy
6.3.1. Leuprolide
6.3.2. Goserelin
6.3.3. Triptorelin
6.3.4. Degarelix
6.3.5. Relugolix
6.4. Targeted therapy
6.4.1. Rucaparib
6.4.2. Olaparib
6.4.3. Talazoparib
6.4.4. Niraparib plus abiraterone
6.5. Immunotherapy
6.5.1. Dostarlimab
6.5.2. Pembrolizumab
6.5.3. Sipuleucel-T
6.6. Surgery
6.6.1. Radical prostatectomy
6.6.2. Transurethral resection of the prostate (TURP)
6.6.3. Orchiectomy
6.7. Radioligand Therapy
7. INDIA PROSTATE CANCER TREATMENT MARKET: BY END USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
7.1.2. Market Attractiveness Index, By End User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Oncology Centers
7.4. Rehabilitation Centers
7.5. Others
8. INDIA PROSTATE CANCER TREATMENT MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Sun Pharmaceutical Industries Ltd*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. Dr. Reddy’s Laboratories
10.3. Hetero Healthcare
10.4. Alkem Labs
10.5. Astellas Pharma
10.6. AstraZeneca
10.7. Bayer AG
10.8. Dendreon Pharmaceuticals
10.9. Ferring B.V
10.10. Johnson & Johnson (Janssen Pharmaceuticals) (LIST NOT EXHAUSTIVE)
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
LIST OF TABLES
Table 1 India Prostate Cancer Treatment Market Value, By Stage, 2025, 2029 & 2033 (US$ Million)
Table 2 India Prostate Cancer Treatment Market Value, By Therapy Type, 2025, 2029 & 2033 (US$ Million)
Table 3 India Prostate Cancer Treatment Market Value, By End User, 2025, 2029 & 2033 (US$ Million)
Table 4 India Prostate Cancer Treatment Market Value, By Stage, 2025, 2029 & 2033 (US$ Million)
Table 5 India Prostate Cancer Treatment Market Value, By Stage, 2022-2033 (US$ Million)
Table 6 India Prostate Cancer Treatment Market Value, By Therapy Type, 2025, 2029 & 2033 (US$ Million)
Table 7 India Prostate Cancer Treatment Market Value, By Therapy Type, 2022-2033 (US$ Million)
Table 8 India Prostate Cancer Treatment Market Value, By End User, 2025, 2029 & 2033 (US$ Million)
Table 9 India Prostate Cancer Treatment Market Value, By End User, 2022-2033 (US$ Million)
Table 10 Sun Pharmaceutical Industries Ltd.: Overview
Table 11 Sun Pharmaceutical Industries Ltd.: Product Portfolio
Table 12 Sun Pharmaceutical Industries Ltd.: Key Developments
Table 13 Dr. Reddy’s Laboratories: Overview
Table 14 Dr. Reddy’s Laboratories: Product Portfolio
Table 15 Dr. Reddy’s Laboratories: Key Developments
Table 16 Hetero Healthcare: Overview
Table 17 Hetero Healthcare: Product Portfolio
Table 18 Hetero Healthcare: Key Developments
Table 19 Alkem Labs: Overview
Table 20 Alkem Labs: Product Portfolio
Table 21 Alkem Labs: Key Developments
Table 22 Astellas Pharma: Overview
Table 23 Astellas Pharma: Product Portfolio
Table 24 Astellas Pharma: Key Developments
Table 25 AstraZeneca: Overview
Table 26 AstraZeneca: Product Portfolio
Table 27 AstraZeneca: Key Developments
Table 28 Bayer AG: Overview
Table 29 Bayer AG: Product Portfolio
Table 30 Bayer AG: Key Developments
Table 31 Dendreon Pharmaceuticals: Overview
Table 32 Dendreon Pharmaceuticals: Product Portfolio
Table 33 Dendreon Pharmaceuticals: Key Developments
Table 34 Ferring B.V: Overview
Table 35 Ferring B.V.: Product Portfolio
Table 36 Ferring B.V.: Key Developments
Table 37 Johnson & Johnson (Janssen Pharmaceuticals): Overview
Table 38 Johnson & Johnson (Janssen Pharmaceuticals): Product Portfolio
Table 39 Johnson & Johnson (Janssen Pharmaceuticals): Key Developments
Table 1 India Prostate Cancer Treatment Market Value, By Stage, 2025, 2029 & 2033 (US$ Million)
Table 2 India Prostate Cancer Treatment Market Value, By Therapy Type, 2025, 2029 & 2033 (US$ Million)
Table 3 India Prostate Cancer Treatment Market Value, By End User, 2025, 2029 & 2033 (US$ Million)
Table 4 India Prostate Cancer Treatment Market Value, By Stage, 2025, 2029 & 2033 (US$ Million)
Table 5 India Prostate Cancer Treatment Market Value, By Stage, 2022-2033 (US$ Million)
Table 6 India Prostate Cancer Treatment Market Value, By Therapy Type, 2025, 2029 & 2033 (US$ Million)
Table 7 India Prostate Cancer Treatment Market Value, By Therapy Type, 2022-2033 (US$ Million)
Table 8 India Prostate Cancer Treatment Market Value, By End User, 2025, 2029 & 2033 (US$ Million)
Table 9 India Prostate Cancer Treatment Market Value, By End User, 2022-2033 (US$ Million)
Table 10 Sun Pharmaceutical Industries Ltd.: Overview
Table 11 Sun Pharmaceutical Industries Ltd.: Product Portfolio
Table 12 Sun Pharmaceutical Industries Ltd.: Key Developments
Table 13 Dr. Reddy’s Laboratories: Overview
Table 14 Dr. Reddy’s Laboratories: Product Portfolio
Table 15 Dr. Reddy’s Laboratories: Key Developments
Table 16 Hetero Healthcare: Overview
Table 17 Hetero Healthcare: Product Portfolio
Table 18 Hetero Healthcare: Key Developments
Table 19 Alkem Labs: Overview
Table 20 Alkem Labs: Product Portfolio
Table 21 Alkem Labs: Key Developments
Table 22 Astellas Pharma: Overview
Table 23 Astellas Pharma: Product Portfolio
Table 24 Astellas Pharma: Key Developments
Table 25 AstraZeneca: Overview
Table 26 AstraZeneca: Product Portfolio
Table 27 AstraZeneca: Key Developments
Table 28 Bayer AG: Overview
Table 29 Bayer AG: Product Portfolio
Table 30 Bayer AG: Key Developments
Table 31 Dendreon Pharmaceuticals: Overview
Table 32 Dendreon Pharmaceuticals: Product Portfolio
Table 33 Dendreon Pharmaceuticals: Key Developments
Table 34 Ferring B.V: Overview
Table 35 Ferring B.V.: Product Portfolio
Table 36 Ferring B.V.: Key Developments
Table 37 Johnson & Johnson (Janssen Pharmaceuticals): Overview
Table 38 Johnson & Johnson (Janssen Pharmaceuticals): Product Portfolio
Table 39 Johnson & Johnson (Janssen Pharmaceuticals): Key Developments
LIST OF FIGURES
Figure 1 India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 2 India Prostate Cancer Treatment Market Share, By Stage, 2024 & 2033 (%)
Figure 3 India Prostate Cancer Treatment Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 4 India Prostate Cancer Treatment Market Share, By End User, 2024 & 2033 (%)
Figure 5 India Prostate Cancer Treatment Market Y-o-Y Growth, By Stage, 2023-2033 (%)
Figure 6 Stage I Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 7 Stage II Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 8 Stage III Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 9 Stage IV Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 10 India Prostate Cancer Treatment Market Y-o-Y Growth, By Therapy Type, 2023-2033 (%)
Figure 11 Radiation Therapy Type in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 12: Chemotherapy Type in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 13 Hormone therapy Therapy Type in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 14 Targeted Therapy Type in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 15 Immunotherapy Type in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 16 Surgery Therapy Type in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 17 India Prostate Cancer Treatment Market Y-o-Y Growth, By End User, 2023-2033 (%)
Figure 18 Hospitals End User in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 19 Oncology Centers End User in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 20 Rehabilitation Centers End User in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 21: Other End User in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 22 Sun Pharmaceutical Industries Ltd.: Financials
Figure 23 Dr. Reddy’s Laboratories: Financials
Figure 24 Hetero Healthcare: Financials
Figure 25 Alkem Labs: Financials
Figure 26 Astellas Pharma: Financials
Figure 27 AstraZeneca: Financials
Figure 28 Bayer AG: Financials
Figure 29 Dendreon Pharmaceuticals: Financials
Figure 30 Ferring B.V: Financials
Figure 31 Johnson & Johnson (Janssen Pharmaceuticals): Financials
Figure 1 India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 2 India Prostate Cancer Treatment Market Share, By Stage, 2024 & 2033 (%)
Figure 3 India Prostate Cancer Treatment Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 4 India Prostate Cancer Treatment Market Share, By End User, 2024 & 2033 (%)
Figure 5 India Prostate Cancer Treatment Market Y-o-Y Growth, By Stage, 2023-2033 (%)
Figure 6 Stage I Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 7 Stage II Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 8 Stage III Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 9 Stage IV Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 10 India Prostate Cancer Treatment Market Y-o-Y Growth, By Therapy Type, 2023-2033 (%)
Figure 11 Radiation Therapy Type in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 12: Chemotherapy Type in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 13 Hormone therapy Therapy Type in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 14 Targeted Therapy Type in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 15 Immunotherapy Type in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 16 Surgery Therapy Type in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 17 India Prostate Cancer Treatment Market Y-o-Y Growth, By End User, 2023-2033 (%)
Figure 18 Hospitals End User in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 19 Oncology Centers End User in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 20 Rehabilitation Centers End User in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 21: Other End User in India Prostate Cancer Treatment Market Value, 2022-2033 (US$ Million)
Figure 22 Sun Pharmaceutical Industries Ltd.: Financials
Figure 23 Dr. Reddy’s Laboratories: Financials
Figure 24 Hetero Healthcare: Financials
Figure 25 Alkem Labs: Financials
Figure 26 Astellas Pharma: Financials
Figure 27 AstraZeneca: Financials
Figure 28 Bayer AG: Financials
Figure 29 Dendreon Pharmaceuticals: Financials
Figure 30 Ferring B.V: Financials
Figure 31 Johnson & Johnson (Janssen Pharmaceuticals): Financials
